Plant · Scientific monograph
Crataegus monogyna
Hawthorn
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Cardiovascular System, Blood Pressure Mechanisms, Oxidative Stress Research
Research overview
Historical use
Crataegus monogyna (common hawthorn) has been used in European and Chinese traditional medicine for over 2,000 years. Medieval European herbalists prescribed the berries, leaves, and flowers for 'weak heart,' dropsy (oedema), and palpitations. In Traditional Chinese Medicine, Shan Zha (C. pinnatifida) is used to resolve blood stasis, food stagnation, and cardiovascular complaints. The plant was formally introduced into Western pharmacopoeia in the late 19th century as a cardiotonic herb, and by the 1980s standardised WS 1442 extract had entered European clinical trials for heart failure.
Modern research context
Hawthorn is one of the best-evidenced herbal medicines for cardiovascular applications. A Cochrane systematic review of 14 RCTs (n=900) found WS 1442 extract (900 mg/day) significantly improved exercise tolerance and reduced symptoms in NYHA class II–III heart failure [1]. A meta-analysis of hawthorn extract for blood pressure demonstrated significant diastolic BP reduction (~3 mmHg) across multiple controlled trials [2]. The landmark SPICE trial (n=2,681, 24 months) confirmed safety in mild-to-moderate CHF but found the primary endpoint (time-to-first-event) was not met, with post-hoc analysis showing possible harm in patients with LVEF <25% [3]. A comprehensive review of hawthorn pharmacology confirmed positive inotropic, vasodilatory, antioxidant, and anti-arrhythmic mechanisms [4]. A 2011 systematic review of 17 controlled trials confirmed significant anxiolytic effects and lipid-lowering activity in hypercholesterolaemic patients [5].
Adverse effects
Generally well-tolerated at standard doses. Reported adverse effects in clinical trials include nausea, dizziness, gastrointestinal discomfort, headache, and palpitations at high doses. The SPICE trial reported no significant increase in serious adverse events versus placebo at 900 mg/day WS 1442 over 24 months [3]. Hypotension risk increases when combined with antihypertensive medications.
Contraindications
Contraindicated in severe heart failure (LVEF <25%) based on SPICE trial data [3]. Concurrent use with cardiac glycosides (digoxin) requires close monitoring due to additive inotropic and chronotropic effects. Avoid with PDE-5 inhibitors and nitrates due to additive vasodilation. Insufficient safety data in pregnancy — avoid [1, 4].
Clinical and phytochemical data
Used part
Berries (Fructus Crataegi), leaves with flowers (Folium Crataegi cum Flore)
Primary active compounds
Oligomeric proanthocyanidins (OPCs) — primary cardioactive fraction
Vitexin-2-O-rhamnoside (flavone glycoside)
Hyperoside (flavonol glycoside)
Rutin
Chlorogenic acid
Epicatechin
Quercetin
Ursolic and oleanolic acids (pentacyclic triterpenes)
Mechanism of action
Positive inotropic effect: OPCs inhibit phosphodiesterase III/IV, elevating intracellular cAMP and enhancing myocardial contractility without increasing oxygen demand. Vasodilation: Flavonoids stimulate endothelial eNOS, increasing NO-mediated vascular relaxation and reducing peripheral resistance. Anti-arrhythmic: Hawthorn prolongs the effective refractory period by modulating cardiac potassium channels (IKr inhibition), reducing arrhythmia susceptibility. Antioxidant cardioprotection: OPCs and flavonoids scavenge ROS, inhibit LDL oxidation, and reduce NF-κB-mediated vascular inflammation via the Nrf2/HO-1 pathway [4].
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — OPCs and flavonoids are absorbed in the small intestine with moderate oral bioavailability (~30–40%) limited by first-pass metabolism, gut wall efflux, and poor aqueous solubility of some glycosides. Peak plasma concentrations of vitexin derivatives occur at 2–4 hours post-dose.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — OPCs and flavonoids distribute preferentially to cardiovascular tissues, vascular endothelium, liver, and kidneys. Plasma protein binding of flavonoid aglycones exceeds 80%, predominantly to albumin.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Hepatic phase II conjugation (glucuronidation, sulfation) of flavonoid aglycones. OPCs are partially hydrolysed by colonic microbiota to monomeric catechins before systemic absorption.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primarily renal excretion of phase II-conjugated flavonoid metabolites. Terminal half-life of major flavonoids estimated at 2–6 hours in animal models.
Safety and interactions
Drug interactions
Digoxin — additive positive inotropic and chronotropic effects; monitor digoxin levels. Antihypertensives — additive hypotensive effect; monitor BP. Nitrates and PDE-5 inhibitors — additive vasodilation; risk of hypotension. Anticoagulants — theoretical interaction via platelet OPC effects; monitor [1, 4].
Toxicity
No significant hepatotoxicity or haematological toxicity signals in the SPICE trial at 900 mg/day over 24 months (n=2,681) [3]. Doses well above the therapeutic range may cause hypotension and sedation. No LD50 data in humans. At pharmacopoeial doses, no serious adverse events have been identified in available clinical data; long-term safety data beyond 24 months are limited.
Special precautions
Pregnancy
Insufficient safety data. Avoid medicinal-dose preparations during pregnancy.
Lactation
Insufficient safety data. Avoid during lactation.
Hepatic impairment
No specific data. Standard dose precautions apply; hawthorn is not known to be hepatotoxic.
Renal impairment
No specific data. Standard dose precautions apply at pharmacopoeial doses.
Sources and references
- [1] - Pittler MH, Guo R, Ernst E., "Hawthorn extract for treating chronic heart failure.", Cochrane Database Syst Rev, 2008, PMID: 18843604
- [2] - Walker AF, Marakis G, Morris AP, Robinson PA., "Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension.", Phytother Res, 2002, PMID: 12710811
- [3] - Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M., "The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial.", Eur J Heart Fail, 2008, PMID: 18757091
- [4] - Tassell MC, Kingston R, Gilroy D, Lehane M, Furey A., "Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease.", Pharmacogn Rev, 2010, PMID: 22228954
- [5] - Dalli E, Colomer E, Tormos MC et al., "Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial.", Phytomedicine, 2011, PMID: 21419621